These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35083158)

  • 1. Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.
    Pecorelli N; Licinio AW; Guarneri G; Aleotti F; Crippa S; Reni M; Falconi M; Balzano G
    Front Oncol; 2021; 11():812102. PubMed ID: 35083158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
    Front Oncol; 2020; 10():41. PubMed ID: 32083002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.
    He J; Lv N; Yang Z; Luo Y; Zhong W; Wu C
    Int J Surg; 2024 Jun; 110(6):3900-3909. PubMed ID: 38935819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
    van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
    Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
    Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
    Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis.
    Yang SQ; Zou RQ; Dai YS; Li FY; Hu HJ
    Updates Surg; 2024 Jan; 76(1):1-15. PubMed ID: 37639177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
    Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
    Front Oncol; 2020; 10():1112. PubMed ID: 32850319
    [No Abstract]   [Full Text] [Related]  

  • 9. Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution.
    Recio-Boiles A; Vondrak J; Veeravelli S; Mancuso JJ; Saboda K; Roe DJ; Riaz IB; Scott AJ; Elquza E; McBride A; Babiker HM
    Ann Pancreat Cancer; 2020 Mar; 3():. PubMed ID: 32313882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials.
    Aliseda D; Martí-Cruchaga P; Zozaya G; Blanco N; Ponz M; Chopitea A; Rodríguez J; Castañón E; Pardo F; Rotellar F
    BJS Open; 2024 Sep; 8(5):. PubMed ID: 39329454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis.
    da Costa WL; Tran Cao HS; Sheetz KH; Gu X; Norton EC; Massarweh NN
    Ann Surg Oncol; 2021 Jun; 28(6):3186-3195. PubMed ID: 33174146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
    Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
    Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials.
    Ghanem I; Lora D; Herradón N; de Velasco G; Carretero-González A; Jiménez-Varas MÁ; Vázquez de Parga P; Feliu J
    ESMO Open; 2022 Jun; 7(3):100485. PubMed ID: 35580504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Zou Y; Gao S; Yu X; Zhou T; Xie Y; Guo X; An R; Wang X; Zhao T; Chang A; Gao C; Yu J; Hao J
    Int J Surg; 2023 Jun; 109(6):1573-1583. PubMed ID: 37132194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
    Versteijne E; van Dam JL; Suker M; Janssen QP; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Tienhoven G; van Eijck CHJ;
    J Clin Oncol; 2022 Apr; 40(11):1220-1230. PubMed ID: 35084987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
    Fossaert V; Mimmo A; Rhaiem R; Rached LJ; Brasseur M; Brugel M; Pegoraro F; Sanchez S; Bouché O; Kianmanesh R; Piardi T
    Front Oncol; 2022; 12():980659. PubMed ID: 36387257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer.
    Shrestha B; Sun Y; Faisal F; Kim V; Soares K; Blair A; Herman JM; Narang A; Dholakia AS; Rosati L; Hacker-Prietz A; Chen L; Laheru DA; De Jesus-Acosta A; Le DT; Donehower R; Azad N; Diaz LA; Murphy A; Lee V; Fishman EK; Hruban RH; Liang T; Cameron JL; Makary M; Weiss MJ; Ahuja N; He J; Wolfgang CL; Huang CY; Zheng L
    Cancer Med; 2017 Jul; 6(7):1552-1562. PubMed ID: 28639410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
    Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
    Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis.
    Uson Junior PLS; Carvalho L; Fernandes MLC; Botrus G; de Souza Martins R; da Silva EF; Dos Santos SSMB; Taniwaki L; Taranto P; Dutra ACP; de Oliveira Filho JB; Araujo SEA; Moura F
    Sci Rep; 2022 Aug; 12(1):13592. PubMed ID: 35948602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.